睿知中国医院研究地图
候选清单

济南山东第一医科大学

山东第一医科大学附属中心医院(济南市中心医院)

Central Hospital Affiliated to Shandong First Medical University

在本站收录的 61 种疾病中,这家医院列在其中 11 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

山东第一医科大学附属中心医院(济南市中心医院)的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
  2. 胃癌Stomach cancer31 篇牵头论文
  3. 肺癌Lung cancer59 篇牵头论文
  4. 乳腺癌Breast cancer21 篇牵头论文牵头 1 项开放试验
  5. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma6 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  8. 血友病 AHaemophilia A1 篇牵头论文
  9. 冠心病Coronary heart disease6 篇牵头论文
  10. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  11. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:鼻咽癌、肝细胞癌、胰腺癌、胶质瘤、肝母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、先天性心脏病、脊柱侧弯、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 1120242025: 112025

济南有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
    分期
    I/II期
    开始
    2026-03
    发布
    登记号
    NCT07405151

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、厦门、合肥、徐州、杭州、济南、郑州

  2. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗放疗
论文中的科室消化/肝病科肿瘤内科病理/检验科
牵头的论文4
  1. High MRPL12 expression drives esophageal cancer proliferation, invasion and migration.2025Bulletin du cancer
  2. Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.2024Cancer communications (London, England)RCT免费全文
  3. Circ_0006948 Contributes to Cell Growth, Migration, Invasion and Epithelial-Mesenchymal Transition in Esophageal Carcinoma.2022Digestive diseases and sciences
  4. MicroRNA-210 targets FBXO31 to inhibit tumor progression and regulates the Wnt/β-catenin signaling pathway and EMT in esophageal squamous cell carcinoma.2021Thoracic cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)正在招募NCT07405151研究中心I/II期2026-03 启动
  2. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  3. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  4. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
PubMed 以外找到的论文(未计入)5
  1. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technology论文
  2. 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)2024Annals of Oncology论文
  3. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncology会议摘要
  4. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  5. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 31 篇,占 0.3%。

牵头论文
31
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 5520222023: 7720232024: 9920242025: 552025

济南有 7 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    发布
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  3. 正在招募
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    分期
    I期
    开始
    2022-02
    发布
    登记号
    NCT05262491

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、成都、杭州、济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜营养与康复影像与人工智能
论文中的科室消化/肝病科肿瘤内科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文31
  1. MTF1 attenuates ferroptosis and cuproptosis synergistic potentiation in gastric cancer.2026Cell death and differentiation
  2. DKN-01 Suppresses Gastric Cancer Progression Through Activating cGAS-STING Pathway to Block Macrophage M2 Polarization.2025Applied biochemistry and biotechnology
  3. Helicobacter pylori-induced aberrant methylation of ID4 mediated by DNMT3B drives gastric cancer progression via DEC1-SHH signaling pathway.2025Cell death & disease免费全文
  4. GLI2 inhibits cisplatin sensitivity in gastric cancer through DEC1/ZEB1 mediated EMT.2025Cell death & disease免费全文
  5. Sanguinarine Inhibits Gastric Cancer Progression by Targeting the NOS2/SOD1 Axis to Promote Ferroptosis.2025The American journal of Chinese medicine
  6. Helicobacter pylori infection induces STAT3/MYBL2/NF-κB axis to promote gastric cancer progression.2025Tissue & cell
  7. A Novel Signature Based on m6A Regulator-Mediated Genes Along Glycolytic Pathway Predicts Prognosis and Immunotherapy Responses of Gastric Cancer Patients.2024Advanced biology
  8. Fabrication of Nickel/Zinc Oxide Nanocomposites from Citrus sinensis Extract Prompts Apoptosis Through Impeding JAK/STAT3 Signaling in Gastric Cancer.2024Applied biochemistry and biotechnology
  9. Effect of Intensive Nursing Management on Quality of Life and Mental Health in Elderly Gastric Cancer Patients Undergoing Chemotherapy: A Retrospective Study.2024British journal of hospital medicine (London, England : 2005)
  10. Positive GLI1/INHBA feedback loop drives tumor progression in gastric cancer.2024Cancer science免费全文
  11. Myricetin Induces Ferroptosis and Inhibits Gastric Cancer Progression by Targeting NOX4.2024Journal of agricultural and food chemistry
  12. ROR2 promotes cell cycle progression and cell proliferation through the PI3K/AKT signaling pathway in gastric cancer.2024Molecular carcinogenesis
  13. PKP2 induced by YAP/TEAD4 promotes malignant progression of gastric cancer.2024Molecular carcinogenesis
  14. Virulence gene polymorphisms in Shandong Helicobacter pylori strains and their relevance to gastric cancer.2024PloS one免费全文
  15. Amino acid deletions at positions 893 and 894 of cytotoxin-associated gene A protein affect Helicobacter pylori gastric epithelial cell interactions.2024World journal of gastroenterology免费全文
  16. PHKG2 regulates RSL3-induced ferroptosis in Helicobacter pylori related gastric cancer.2023Archives of biochemistry and biophysics
  17. Helicobacter pylori-induced aberrant demethylation and expression of GNB4 promotes gastric carcinogenesis via the Hippo-YAP1 pathway.2023BMC medicine免费全文
  18. Targeting Hippo pathway: A novel strategy for Helicobacter pylori-induced gastric cancer treatment.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  19. SUMOylation of TUFT1 is essential for gastric cancer progression through AKT/mTOR signaling pathway activation.2023Cancer science免费全文
  20. Clinical and prognostic features of E-cadherin in adenocarcinoma of the esophagogastric junction patients.2023European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  21. Potential Effects of FGFR4 in the Helicobacter pylori-Induced Inflammatory Carcinoma Transformation.2023Gastroenterology
  22. STAT5A modulates gastric cancer progression via upregulation of CD44.2023Genomics
  23. Knockdown circZNF131 Inhibits Cell Progression and Glycolysis in Gastric Cancer Through miR-186-5p/PFKFB2 Axis.2022Biochemical genetics
  24. Relationship between glutathione S-transferase M1 gene polymorphism and gastric cancer.2022Cellular and molecular biology (Noisy-le-Grand, France)
  25. Reciprocal Expression of Differentiated Embryonic Chondrocyte Expressed Genes Result in Functional Antagonism in Gastric Cancer.2022Digestive diseases and sciences
  26. Clinicopathological Significance of STAT3 and p-STAT3 among 91 Patients with Adenocarcinoma of the Esophagogastric Junction.2022Disease markers免费全文
  27. DEC1 promotes progression of Helicobacter pylori-positive gastric cancer by regulating Akt/NF-κB pathway.2022Journal of cellular and molecular medicine免费全文
  28. Effect of LAMA4 on Prognosis and Its Correlation with Immune Infiltration in Gastric Cancer.2021BioMed research international免费全文
  29. Long noncoding RNA NR2F1-AS1 plays a carcinogenic role in gastric cancer by recruiting transcriptional factor SPI1 to upregulate ST8SIA1 expression.2021Bioengineered免费全文
  30. Andrographolide Induces Apoptosis in Gastric Cancer Cells through Reactivation of p53 and Inhibition of Mdm-2.2021Doklady. Biochemistry and biophysics
  31. LncPSCA in the 8q24.3 risk locus drives gastric cancer through destabilizing DDX5.2021EMBO reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  2. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor正在招募NCT05262491研究中心I期2022-02 启动
  3. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  4. Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer进行中,不再招募NCT06609759研究中心2024-01 启动
  5. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  6. Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer进行中,不再招募NCT06157216研究中心不分期2023-10 启动
  7. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer进行中,不再招募NCT05586061研究中心II期2023-02 启动
  8. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  9. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  10. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.已终止NCT05188209研究中心II期2021-12 启动
  11. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  12. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  13. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 59 篇,占 0.2%。

牵头论文
59
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
16
由其他机构牵头
每年牵头的论文数
2021: 131320212022: 9920222023: 131320232024: 8820242025: 15152025

济南有 9 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 16

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2026-01
    发布
    登记号
    NCT07222566

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、太原、广州、成都、扬州、新乡、杭州、武汉、江门、洛阳、济南、温州、福州、襄阳、郑州、重庆、长春、长沙

  2. 正在招募
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07416474

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛

  3. 正在招募
    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
    分期
    II/III期
    开始
    2025-01
    发布
    登记号
    NCT06712316

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、台州、扬州、杭州、武汉、汕头、济南、石家庄、苏州、蚌埠、重庆、长春、长沙

  4. 正在招募
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    分期
    III期
    开始
    2025-02
    发布
    登记号
    NCT06712355

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南昌、台州、合肥、哈尔滨、太原、广州、扬州、新乡、杭州、武汉、汕头、济南、温州、石家庄、福州、苏州、蚌埠、襄阳、郑州、重庆、长春

  5. 正在招募
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    分期
    III期
    开始
    2025-07
    发布
    登记号
    NCT06758401

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、常州、广州、徐州、成都、杭州、武汉、洛阳、济南、温州、福州、西安、郑州、长沙

  6. 正在招募
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06890598

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、佛山、北京、南宁、台州、哈尔滨、天津、安阳、广州、成都、杭州、武汉、汕头、洛阳、济南、深圳、苏州、西安、重庆、长沙

  7. 正在招募
    A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
    分期
    I/II期
    开始
    2025-05
    发布
    登记号
    NCT06892548

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心临沂、北京、南京、南宁、南昌、厦门、合肥、宜昌、广州、徐州、成都、新乡、杭州、济南、福州、襄阳、西安、郑州、长春

  8. 正在招募
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    分期
    II期
    开始
    2025-06
    发布
    登记号
    NCT06962865

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心临沂、北京、哈尔滨、天津、太原、广州、成都、昆明、杭州、桂林、武汉、济南、温州、烟台、石家庄、福州、襄阳、郑州、重庆、长春、长沙

  9. 正在招募
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    分期
    I/II期
    开始
    2025-09
    发布
    登记号
    NCT07111520

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、南昌、合肥、天津、广州、徐州、成都、扬州、新乡、武汉、济南、石家庄、福州、苏州、襄阳、重庆、长春、青岛

  10. 正在招募
    A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
    分期
    III期
    开始
    2025-09
    发布
    登记号
    NCT07144280

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南宁、南昌、台州、合肥、哈尔滨、常州、广州、徐州、成都、杭州、武汉、济南、福州、西安、郑州、重庆、长沙

  11. 正在招募
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07182682

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙

  12. 正在招募
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07185997

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、佛山、北京、南京、南宁、南昌、南通、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、新乡、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、潍坊、石家庄、福州、郑州、重庆、长沙、青岛

  13. 正在招募
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
    分期
    II期
    开始
    2023-12
    发布
    登记号
    NCT06010329

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南京、南昌、哈尔滨、广州、成都、杭州、武汉、济南、郑州

  14. 正在招募
    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06119581

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、台州、哈尔滨、天津、宜昌、常州、广州、成都、杭州、武汉、济南、海口、湛江、福州、襄阳、西安、长沙

  15. 正在招募
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06170788

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、广州、徐州、成都、无锡、杭州、武汉、济南、湛江、石家庄、福州、襄阳、郑州、长沙

  16. 正在招募
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    分期
    III期
    开始
    2022-03
    发布
    登记号
    NCT04928846

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科临床试验/研究机构病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文59
  1. The α5-nAChR/GINS4 axis contributed to nicotine-promoted lung adenocarcinoma progression.2026Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  2. Novel Evolutionarily Conserved Oncogene COA4 is Driven by KRAS Mutant and Promotes Cancer Metastasis Through Dual Mitochondrial Metabolism-Dependent and -Independent Mechanisms.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Clinical evaluation of a novel-developed clone 3E2 for the detection of PD-L1 expression status in lung adenocarcinoma.2025BMC cancer免费全文
  4. Investigation into the Spatial Heterogeneity of Lung Composite Large-Cell Neuroendocrine Carcinoma Spatial Transcriptomic Analysis of Combined Large-Cell Neuroendocrine Carcinoma.2025Cancer biotherapy & radiopharmaceuticals
  5. The diagnostic value of serum exosomal SNORD116 and SNORA21 for NSCLC patients.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  6. Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer.2025Frontiers in immunology免费全文
  7. The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.2025Frontiers in immunology免费全文
  8. Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review.2025Frontiers in immunology免费全文
  9. ZEB1 Contributes to Drug Resistance Through Canonical Wnt Signaling in Lung Cancer.2025IUBMB life
  10. Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.2025International journal of cancer免费全文
  11. Simultaneous treatment of pulmonary ground-glass opacity nodules with microwave ablation and coaxial puncture biopsy.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  12. Clinical application of microwave ablation combined with coaxial needle biopsy using different sequences for treating lung nodules suggestive of malignancy.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  13. Resolving the spatial and cellular architecture of intra-tumor heterogeneity by multi-region dissection of lung adenocarcinoma.2025Journal of genetics and genomics = Yi chuan xue bao
  14. Correlation of Peripheral Blood CD4/CD8 Ratio with Efficacy and Prognosis in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors.2025Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  15. Prognostic Significance of CD4+ Tumour Infiltrating Lymphocytes in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors Therapy.2025Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  16. The role of glutathione peroxidase 4 in the progression, drug resistance, and targeted therapy of non-small cell lung cancer.2025Oncology research免费全文
  17. Lung Cancer with Axillary Lymph Node Involvement: A Case Report and Literature Review on a Rare Mode of Metastasis.2024Annals of clinical and laboratory science
  18. Feasibility of an artificial intelligence system for tumor response evaluation.2024BMC medical imaging免费全文
  19. Nicotine promotes M2 macrophage polarization through α5-nAChR/SOX2/CSF-1 axis in lung adenocarcinoma.2024Cancer immunology, immunotherapy : CII免费全文
  20. Dual-Phase Enhanced CT-Derived Radiomics Nomogram for Progression-Free Survival Prediction in Stage IV Lung Adenocarcinoma.2024Cancer medicine免费全文
  21. Evaluation of an Algorithm for the Segmentation of Lung Nodules in Computerized Tomography Images based on the Automatic Location of a Threshold.2024Current medical imaging
  22. The innovative checkpoint inhibitors of lung adenocarcinoma, cg09897064 methylation and ZBP1 expression reduction, have implications for macrophage polarization and tumor growth in lung cancer.2024Journal of translational medicine免费全文
  23. PLEK2 mediates metastasis and invasion via α5-nAChR activation in nicotine-induced lung adenocarcinoma.2024Molecular carcinogenesis
  24. CALU promotes lung adenocarcinoma progression by enhancing cell proliferation, migration and invasion.2024Respiratory research免费全文
  25. Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report.2023BMC pulmonary medicine免费全文
  26. A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC.2023BMC pulmonary medicine免费全文
  27. Multi-classification model incorporating radiomics and clinic-radiological features for predicting invasiveness and differentiation of pulmonary adenocarcinoma nodules.2023Biomedical engineering online免费全文
  28. α5-nAChR/STAT3/CD47 axis contributed to nicotine-related lung adenocarcinoma progression and immune escape.2023Carcinogenesis
  29. Acetylcholine promotes chronic stress-induced lung adenocarcinoma progression via α5-nAChR/FHIT pathway.2023Cellular and molecular life sciences : CMLS免费全文
  30. GRIN2D knockdown suppresses the progression of lung adenocarcinoma by regulating the E2F signalling pathway.2023Cellular signalling
  31. Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.2023Expert review of anticancer therapy
  32. Radiomics nomogram for the prediction of Ki-67 index in advanced non-small cell lung cancer based on dual-phase enhanced computed tomography.2023Journal of cancer research and clinical oncology免费全文
  33. ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer.2023Journal of cell science
  34. Clinical Study of Artificial Intelligence in Imaging Diagnosis of False Positive Lesions of Pulmonary Nodules.2023Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  35. Heat shock protein B7 (HSPB7) inhibits lung adenocarcinoma progression by inhibiting glycolysis.2023Oncology reports免费全文
  36. Role of the cGAS-STING pathway in radiotherapy for non-small cell lung cancer.2023Radiation oncology (London, England)免费全文
  37. Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models.2023Translational research : the journal of laboratory and clinical medicine
  38. Comparison of the BOPPPS model and traditional instructional approaches in thoracic surgery education.2022BMC medical education免费全文
  39. α5-nAChR associated with Ly6E modulates cell migration via TGF-β1/Smad signaling in non-small cell lung cancer.2022Carcinogenesis
  40. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.2022Cell communication and signaling : CCS免费全文
  41. Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants.2022Clinical pharmacology in drug developmentRCT
  42. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.2022Frontiers in immunology免费全文
  43. The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.2022Human cell
  44. Establishment and Validation of a Novel Nomogram for Predicting Distant Metastasis in Patients with Invasive Lung Adenocarcinoma.2022Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  45. Research progress on the occurrence and therapeutic mechanism of ferroptosis in NSCLC.2022Naunyn-Schmiedeberg's archives of pharmacology
  46. The role of α5-nicotinic acetylcholine receptor/NLRP3 signaling pathway in lung adenocarcinoma cell proliferation and migration.2022Toxicology
  47. Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.2021Aging免费全文
  48. Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum.2021BMC cancer免费全文
  49. Assessment of safety margin after microwave ablation of stage I NSCLC with three-dimensional reconstruction technique using CT imaging.2021BMC medical imaging免费全文
  50. Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer.2021Bioscience reports免费全文
  51. Clinical characteristics and outcomes of Chinese patients with KRAS-mutant non-small cell lung cancer after chemotherapy.2021Cancer communications (London, England)免费全文
  52. ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer.2021Cancer letters
  53. Potential chemotherapeutic effect of betalain against human non-small cell lung cancer through PI3K/Akt/mTOR signaling pathway.2021Environmental toxicology
  54. Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC.2021Genes & genomics
  55. Insufficient ablation promotes the metastasis of residual non-small cell lung cancer (NSCLC) cells via upregulating carboxypeptidase A4.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  56. α5-nAChR and survivin: Two potential biological targets in lung adenocarcinoma.2021Journal of cellular physiology
  57. Correlation between Circulating Tumor Cells and Plasma D-dimer and Clinicopathological Characteristics of Patients with Non-small Cell Lung Cancer.2021Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  58. Inhibition Sequence of miR-205 Hinders the Cell Proliferation and Migration of Lung Cancer Cells by Regulating PETN-Mediated PI3K/AKT Signal Pathway.2021Molecular biotechnology
  59. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.2021Theranostics免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)49
  1. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer正在招募NCT07222566研究中心III期2026-01 启动
  2. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)正在招募NCT07416474研究中心III期2026-04 启动
  3. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC正在招募NCT06962865研究中心II期2025-06 启动
  4. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.正在招募NCT06758401研究中心III期2025-07 启动
  5. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations正在招募NCT07185997研究中心III期2025-12 启动
  6. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery正在招募NCT07182682研究中心III期2025-12 启动
  7. Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer正在招募NCT06712355研究中心III期2025-02 启动
  8. A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer正在招募NCT06892548研究中心I/II期2025-05 启动
  9. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)正在招募NCT06712316研究中心II/III期2025-01 启动
  10. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)正在招募NCT07144280研究中心III期2025-09 启动
  11. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer正在招募NCT06890598研究中心III期2025-03 启动
  12. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)正在招募NCT07111520研究中心I/II期2025-09 启动
  13. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer正在招募NCT06119581研究中心III期2023-12 启动
  14. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC正在招募NCT06010329研究中心II期2023-12 启动
  15. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)正在招募NCT06170788研究中心III期2023-12 启动
  16. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)正在招募NCT04928846研究中心III期2022-03 启动
  17. A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC进行中,不再招募NCT06883630研究中心I期2025-03 启动
  18. A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)进行中,不再招募NCT06698042研究中心III期2024-11 启动
  19. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)进行中,不再招募NCT06305754研究中心III期2024-06 启动
  20. A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)进行中,不再招募NCT06593522研究中心II期2024-12 启动
  21. A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer进行中,不再招募NCT06984588研究中心II/III期2024-03 启动
  22. ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors进行中,不再招募NCT05671510研究中心III期2023-06 启动
  23. A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC进行中,不再招募NCT05844150研究中心II期2023-06 启动
  24. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)进行中,不再招募NCT06074588研究中心III期2023-11 启动
  25. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)进行中,不再招募NCT05609968研究中心III期2023-02 启动
  26. Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer进行中,不再招募NCT05740566研究中心III期2023-05 启动
  27. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)进行中,不再招募NCT05668988研究中心III期2022-12 启动
  28. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer已终止NCT04921358研究中心III期2021-07 启动
  29. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)进行中,不再招募NCT05712902研究中心II期2021-07 启动
  30. A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)进行中,不再招募NCT04819100研究中心III期2021-12 启动
  31. A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC已终止NCT04325698研究中心III期2020-06 启动
  32. A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC状态不明NCT04416035研究中心III期2020-08 启动
  33. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  34. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors已完成NCT04215978研究中心I期2020-01 启动
  35. Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer已完成NCT04205812研究中心III期2020-09 启动
  36. A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer已完成NCT04294810研究中心III期2020-03 启动
  37. A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer已完成NCT04619797研究中心II/III期2020-12 启动
  38. Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer已完成NCT04005716研究中心III期2019-07 启动
  39. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer状态不明NCT04641754研究中心II期2019-03 启动
  40. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)进行中,不再招募NCT03974022研究中心I/II期2019-07 启动
  41. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC状态不明NCT03668496研究中心III期2018-11 启动
  42. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer已完成NCT03594747研究中心III期2018-07 启动
  43. A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer已完成NCT03735121研究中心III期2018-12 启动
  44. A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer已完成NCT03663205研究中心III期2018-07 启动
  45. Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)已完成NCT03358875研究中心III期2017-11 启动
  46. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors已完成NCT03037385研究中心I/II期2017-03 启动
  47. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients状态不明NCT04237805研究中心I/II期2016-11 启动
  48. Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)进行中,不再招募NCT02864992研究中心II期2016-09 启动
  49. Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer已完成NCT03117335研究中心III期2011-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.1%。

牵头论文
21
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 7720232024: 5520242025: 552025

济南有 8 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 邀请入组
    Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen
    分期
    不分期
    开始
    2025-11
    发布
    登记号
    NCT07514728

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头:山东第一医科大学附属中心医院(济南市中心医院)济南

  2. 正在招募
    A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
    分期
    I期
    开始
    2025-03
    发布
    登记号
    NCT06738966

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心济南、长春

  3. 正在招募
    A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06841354

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心乌鲁木齐、南京、南宁、厦门、台州、太原、广州、徐州、成都、杭州、武汉、济南、蚌埠、襄阳、西安、郑州、重庆、长春、长沙

  4. 正在招募
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    分期
    III期
    开始
    2025-06
    发布
    登记号
    NCT06966700

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、厦门、合肥、哈尔滨、杭州、武汉、济南、西安、郑州、长春、长沙

  5. 正在招募
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    分期
    II期
    开始
    2023-12
    发布
    登记号
    NCT06107686

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南宁、南昌、台州、合肥、哈尔滨、太原、广州、徐州、成都、杭州、桂林、梅州、武汉、汕头、沈阳、济南、潍坊、苏州、襄阳、西安、郑州、重庆、长春、长沙、青岛

  6. 正在招募
    A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
    分期
    I期
    开始
    2022-08
    发布
    登记号
    NCT05461768

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心广州、武汉、济南、福州、郑州

  7. 正在招募
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    分期
    III期
    开始
    2022-01
    发布
    登记号
    NCT05851014

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、临沂、佛山、南京、南宁、南昌、合肥、宁波、广州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、银川、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科放疗科眼科/神经眼科
牵头的论文21
  1. Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis.2025BMC cancer免费全文
  2. TUFT1 regulates cancer progression by suppressing centrosome amplification and mitotic spindle multipolarity.2025Cell death & disease免费全文
  3. Investigating the molecular mechanisms of phytochemicals targeting Ras-related C3 botulinum toxin substrate 1 (Rac1) to inhibit breast cancer metastasis via endoplasmic reticulum stress and Wnt-PCP signaling pathway.2025Journal of molecular modeling
  4. Value of postmastectomy radiotherapy on overall survival in stage II-III node-negative patients following neoadjuvant therapy: A surveillance, epidemiology, and end results-based population study.2025Science progress免费全文
  5. MRI Radiomics-Based Prediction of Occult Sentinel Lymph Node Metastasis and D2-40 Expression in Breast Cancer.2025Technology in cancer research & treatment免费全文
  6. Prediction of lymphovascular invasion in invasive breast cancer based on clinical-MRI radiomics features.2024BMC medical imaging免费全文
  7. Themis: advancing precision oncology through comprehensive molecular subtyping and optimization.2024Briefings in bioinformatics免费全文
  8. Study on the differential diagnosis of benign and malignant breast lesions using a deep learning model based on multimodal images.2024Journal of cancer research and therapeutics
  9. Application of rapid rehabilitation surgical concepts in the care of patients with modified radical breast cancer in the perioperative period.2024Minerva surgery
  10. LINC02535 + miR-30a-5p combination enhances proliferation and inhibits apoptosis in metastatic breast Cancer cells.2024Toxicology in vitro : an international journal published in association with BIBRA
  11. Identifying miRNA biomarkers for breast cancer and ovarian cancer: a text mining perspective.2023Breast cancer research and treatment
  12. CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.2023Cancer immunology, immunotherapy : CII免费全文
  13. The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment.2023Cell transplantation免费全文
  14. Small Bowel Metastases From Malignant Phyllodes Breast Tumor Detected by 18 F-FDG PET/CT.2023Clinical nuclear medicine
  15. SGK1 is involved in doxorubicin-induced chronic cardiotoxicity and dysfunction through activation of the NFκB pathway.2023International immunopharmacology
  16. ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer.2023Journal of cell science
  17. The effects of qigong intervention based on the Internet on quality of life and physical fitness in Chinese postoperative breast cancer patients: a protocol of randomized controlled trial.2023Trials免费全文
  18. The Significance of Tumor Microenvironment Score for Breast Cancer Patients.2022BioMed research international免费全文
  19. Long non-coding RNA PVT1 facilitates cell migration and invasion by regulating miR-148a-3p and ROCK1 in breast cancer.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  20. Clinical Value of Total Intravenous Anesthesia with Sufentanil and Propofol in Radical Mastectomy.2022Disease markersRCT免费全文
  21. Application of fluorescein combined with methylene blue in sentinel lymph node biopsy of breast cancer.2021Scientific reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)18
  1. Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen邀请入组NCT07514728牵头方不分期2025-11 启动
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)正在招募NCT06841354研究中心III期2025-03 启动
  3. A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer正在招募NCT06738966研究中心I期2025-03 启动
  4. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)正在招募NCT06966700研究中心III期2025-06 启动
  5. A Study of YL202 in Selected Patients With Advanced Solid Tumors正在招募NCT06107686研究中心II期2023-12 启动
  6. A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer正在招募NCT05851014研究中心III期2022-01 启动
  7. A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors正在招募NCT05461768研究中心I期2022-08 启动
  8. Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors进行中,不再招募NCT06380660研究中心I/II期2024-03 启动
  9. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)进行中,不再招募NCT06065748研究中心III期2023-12 启动
  10. A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer进行中,不再招募NCT05514054研究中心III期2022-10 启动
  11. A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer进行中,不再招募NCT05132582研究中心III期2022-03 启动
  12. A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)进行中,不再招募NCT04961996研究中心III期2021-08 启动
  13. GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer已完成NCT05054751研究中心III期2021-09 启动
  14. A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer状态不明NCT04924699研究中心II/III期2021-06 启动
  15. A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer进行中,不再招募NCT04975308研究中心III期2021-10 启动
  16. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  17. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer已完成NCT03084237研究中心III期2016-11 启动
  18. Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer已完成NCT02482753研究中心III期2015-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 8 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.3%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 332025

济南有 18 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文6
  1. Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi-Omics Analysis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology免费全文
  2. The osteosarcoma immune microenvironment in progression: PLEK as a prognostic biomarker and therapeutic target.2025Frontiers in immunology免费全文
  3. Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies.2025Frontiers in immunology免费全文
  4. m6A-modified circARHGAP12 promotes the aerobic glycolysis of doxorubicin-resistance osteosarcoma by targeting c-Myc.2024Journal of orthopaedic surgery and research免费全文
  5. DEPDC1 as a crucial factor in the progression of human osteosarcoma.2023Cancer medicine免费全文
  6. TRIM59 promotes osteosarcoma progression via activation of STAT3.2022Human cell
早期论文(2016–2020 年)5
  1. MiR-196a promoted cell migration, invasion and the epithelial-mesenchymal transition by targeting HOXA5 in osteosarcoma.2020Cancer biomarkers : section A of Disease markers
  2. Silencing of long-non-coding RNA ANCR suppresses the migration and invasion of osteosarcoma cells by activating the p38MAPK signalling pathway.2019BMC cancer
  3. Downregulation of UBE2T can enhance the radiosensitivity of osteosarcoma in vitro and in vivo.2019Epigenomics
  4. Combination of anginex gene therapy and radiation decelerates the growth and pulmonary metastasis of human osteosarcoma xenografts.2018Cancer medicine
  5. β-Aescin shows potent antiproliferative activity in osteosarcoma cells by inducing autophagy, ROS generation and mitochondrial membrane potential loss.2017Journal of B.U.ON. : official journal of the Balkan Union of Oncology

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 4 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Identification of key genes related to high-risk gastrointestinal stromal tumors using bioinformatics analysis.2018Journal of cancer research and therapeutics

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

济南有 3 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06833983

    年龄 18 岁 至 65 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙

  2. 正在招募
    An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
    分期
    I/II期
    开始
    2024-05
    发布
    登记号
    NCT07644832

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心兰州、合肥、太原、济南、西安、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. Retrospective analysis of clinical data from 171 low-income patients with hemophilia in Shandong Province.2025Scientific reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A正在招募NCT06833983研究中心III期2025-03 启动
  2. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency正在招募NCT07644832研究中心I/II期2024-05 启动
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.进行中,不再招募NCT07684898研究中心III期2026-06 启动
  4. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment进行中,不再招募NCT07663903研究中心III期2026-04 启动
  5. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products已完成NCT06738485研究中心III期2025-01 启动
  6. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A已完成NCT05707351研究中心III期2023-03 启动
  7. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A进行中,不再招募NCT05685238研究中心III期2023-02 启动
  8. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  9. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)已完成NCT05082116研究中心III期2021-09 启动
  10. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A已完成NCT04845399研究中心III期2021-04 启动
  11. A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection已完成NCT04864743研究中心I期2021-06 启动
  12. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors已完成NCT05053139研究中心III期2021-12 启动
  13. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.已完成NCT04456387研究中心III期2020-10 启动
  14. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection状态不明NCT03747653研究中心2019-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.1%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 0020222023: 1120232024: 0020242025: 222025

济南有 6 家医院列在冠心病下全国有 231 家医院列在冠心病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的冠心病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科
牵头的论文6
  1. Reduced contrast agent volume using a heart-rate dependent and free-breathing scanning protocol in coronary computed tomography angiography (CTA) for patients with chronic obstructive pulmonary disease (COPD).2025BMC cardiovascular disordersRCT免费全文
  2. The Predictive Value of Multiparameter Characteristics of Coronary Computed Tomography Angiography for Coronary Stent Implantation.2025Journal of computer assisted tomography
  3. The effect of gum consumption on blood pressure as a risk factor for coronary heart disease: A meta-analysis of controlled trials.2023International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition
  4. Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.2021Journal of cardiovascular pharmacologyRCT免费全文
  5. Application Effect of Meticulous Nursing on Community Elderly Patients with Coronary Heart Disease under the Background of Medical Treatment Partnerships.2021Journal of healthcare engineering免费全文
  6. Influence of sex and menopausal status on the relationship between metabolic syndrome and coronary artery calcification: a Chinese community-based cross-sectional study.2021Menopause (New York, N.Y.)
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Food Frequency Questionnaire (FFQ) for Coronary Heart Disease (CHD) Patients已完成NCT03292055研究中心2017-01 启动
  2. Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting已完成NCT02565615研究中心2016-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

济南有 5 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文2
  1. Low-dose rituximab for the treatment of anti-NMDAR encephalitis in children: a case series study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Pharmaceutical care of rituximab in the treatment of children with refractory anti-NMDAR encephalitis: A case report.2023Medicine免费全文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 2 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Dual gene deficient models of ApcMin/+ mouse in assessing molecular mechanisms of intestinal carcinogenesis.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

山东第一医科大学附属中心医院(济南市中心医院)

Central Hospital Affiliated to Shandong First Medical University

济南

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Jinan Central Hospital; Central Hospital Affiliated to Shandong First Medical University; Jinan Central Hospital Affiliated to Shandong University; Jinan Central Hospital Affiliated to Shandong First Medical University; Jinan Central Hospital. Jinan City; 济南市中心医院

提出更正下载数据